Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Reuter

Showing results (1-10 of 176) with videos related to

Pageof 18
Sort By:
The Lancet. Neurology|October 25, 2018
GBD 2016: still no improvement in the burden of migraineUwe Reuter
The Lancet. Neurology|February 21, 2023
A nasal CGRP receptor antagonist for acute migraine therapyUwe Reuter
The Lancet. Neurology|December 14, 2022
Headache research in 2022: advances and remaining challengesUwe Reuter
The Lancet. Neurology|September 19, 2020
Galcanezumab CONQUERs migraine preventionUwe Reuter
Headache|April 27, 2018
A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in MigraineUwe Reuter
The Lancet. Neurology|August 16, 2014
Anti-CGRP antibodies: a new approach to migraine preventionUwe Reuter
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 5, 2018
The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine TherapyBianca Raffaelli, Uwe Reuter
Cephalalgia : an International Journal of Headache|May 19, 2025
Raising the bar in migraine prevention: Toward freedom and optimal controlAntonio Russo, Uwe Reuter
MMW Fortschritte Der Medizin|November 11, 2017
[Monoclonal antibodies for targeted migraine prevention]Uwe Reuter, H Israel-Willner
Current Opinion in Neurology|February 28, 2017
Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studiesDimos D Mitsikostas, Uwe Reuter
Pageof 18

Showing results (1-10 of 176) with videos related to

Sort By:
Pageof 18
The Lancet. Neurology|October 25, 2018
GBD 2016: still no improvement in the burden of migraineUwe Reuter
The Lancet. Neurology|February 21, 2023
A nasal CGRP receptor antagonist for acute migraine therapyUwe Reuter
The Lancet. Neurology|December 14, 2022
Headache research in 2022: advances and remaining challengesUwe Reuter
The Lancet. Neurology|September 19, 2020
Galcanezumab CONQUERs migraine preventionUwe Reuter
Headache|April 27, 2018
A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in MigraineUwe Reuter
The Lancet. Neurology|August 16, 2014
Anti-CGRP antibodies: a new approach to migraine preventionUwe Reuter
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 5, 2018
The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine TherapyBianca Raffaelli, Uwe Reuter
Cephalalgia : an International Journal of Headache|May 19, 2025
Raising the bar in migraine prevention: Toward freedom and optimal controlAntonio Russo, Uwe Reuter
MMW Fortschritte Der Medizin|November 11, 2017
[Monoclonal antibodies for targeted migraine prevention]Uwe Reuter, H Israel-Willner
Current Opinion in Neurology|February 28, 2017
Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studiesDimos D Mitsikostas, Uwe Reuter
Pageof 18